Does Rallies show 13F holders for CMPX?

Yes. Rallies tracks hedge fund and 13F ownership data for CMPX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is CMPX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CMPX. It does not provide personalized investment advice.

CMPX (Compass Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Compass Therapeutics, Inc. Common Stock (CMPX) is a publicly traded Healthcare sector company. As of May 21, 2026, CMPX trades at $1.85 with a market cap of $329.56M and a P/E ratio of -4.46. CMPX moved +3.87% today. Year to date, CMPX is -62.12%; over the trailing twelve months it is -10.00%. Its 52-week range spans $1.27 to $6.88. Analyst consensus is strong buy with an average price target of $10.11. Rallies surfaces CMPX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns CMPX stock?

Hedge funds tracked by Rallies that own CMPX include Orbimed Advisors and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Compass Therapeutics, Inc. Common Stock.

CMPX Key Metrics

Key financial metrics for CMPX
Metric	Value
Price	$1.85
Market Cap	$329.56M
P/E Ratio	-4.46
EPS	$-0.42
Dividend Yield	0.00%
52-Week High	$6.88
52-Week Low	$1.27
Volume	3.40M
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-66.49M
Gross Margin	0.00%

Top Hedge Funds Holding CMPX

Orbimed Advisors holds 15.22M shares of CMPX, changed +0.00% as of Mar 31, 2026.
Panagora Asset holds 15.84K shares of CMPX, changed -90.72% as of Jun 30, 2025.

Latest CMPX News

Compass Therapeutics Phase 2/3 Tovecimig Achieves 17.1% ORR, Holds $195M Cash — May 5, 2026
Compass Therapeutics Reports 56% PFS Risk Reduction, 17.1% ORR in Biliary Cancer Study — Apr 27, 2026

Recent CMPX Insider Trades

Lerner Neil bought 15.00K (~$28.35K) on Apr 29, 2026.
Anderman Jonathan bought 25.00K (~$47.25K) on Apr 29, 2026.
Schuetz Thomas J. bought 10.00K (~$21.10K) on May 27, 2025.

CMPX Analyst Consensus

12 analysts cover CMPX: 0 strong buy, 11 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $10.11.

Common questions about CMPX

Who owns CMPX stock?: Hedge funds tracked by Rallies that own CMPX include Orbimed Advisors and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Compass Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for CMPX?: Yes. Rallies tracks hedge fund and 13F ownership data for CMPX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is CMPX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CMPX. It does not provide personalized investment advice.